NasdaqCM · Biotechnology

Jade Biosciences (JBIO)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+134.9%

$50.13 average target

$21.34+0.11 (+0.5%)Latest market snapshot · Yahoo Finance

Market cap$1.36B

Cash$461.2M

Quarterly burn$24.1M

Pipeline assets3

Short float16.7%

Clinical portfolio

Jade Biosciences Drug Pipeline

Showing 1 of 3

Asset	Indication	Stage	Milestone	Signals ?
JADE201	Rheumatoid arthritis	Phase 1	Dec 31, 2027	—

Continue with BioPharma ProUnlock 2 additional programs and complete development details.

Unlock Pro

Upcoming milestones

JBIO Catalyst Timeline

1 currently tracked

Dec 31, 2027

JADE201

Phase 1

Rheumatoid arthritis

Data readout

Event details

Company profile

About Jade Biosciences

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.